www.gossamerbio.com
51-200 employees
Gossamer Bio is a clinical-stage biopharmaceutical company dedicated to developing and commercializing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company focuses on enhancing the lives of people living with rare diseases, offering a distinctive approach in its industry by targeting these specific conditions with precision.